8-K: Forte Biosciences Announces Positive Second Quarter Results and Advances FB102 Clinical Program

Forte Biosciences reported its second quarter 2024 financial results and provided an update on the progress of its FB102 clinical program, including the initiation of a celiac disease patient study.

Summary

• Forte Biosciences announced its second quarter 2024 financial results, highlighting progress with its FB102 program.
• The Phase 1 healthy volunteer study for FB102 has been successfully completed, demonstrating a good safety profile.
• Based on these results, Forte is initiating a patient study in celiac disease, with data expected by the second quarter of 2025.
• Research and development expenses decreased to $5.7 million for the three months ended June 30, 2024, compared to $7.1 million for the same period in 2023, primarily due to lower manufacturing costs.
• General and administrative expenses increased to $7.1 million for the three months ended June 30, 2024, compared to $1.9 million for the same period in 2023, mainly due to higher legal and professional fees.
• The company reported a net loss per share of $(0.27) for the three months ended June 30, 2024, compared to $(0.42) for the same period in 2023.
• Forte ended the second quarter with approximately $24.5 million in cash and cash equivalents.
• The company had approximately 36.4 million shares of common stock outstanding as of June 30, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in the FB102 program and promising preclinical data. However, the increase in general and administrative expenses and the decrease in cash reserves are areas of concern that temper the overall positive sentiment.

Positives

• The successful completion of the Phase 1 healthy volunteer study for FB102 indicates a positive safety profile.
• The initiation of a celiac disease patient study represents a significant step forward in the clinical development of FB102.
• Preclinical data suggests FB102 has potential across a variety of autoimmune and autoimmune-related diseases.
• The company has a strong management team with extensive experience in the biotechnology industry.
• FB102 has shown promising results in preclinical studies, including a humanized mouse model of acute GVHD, where it demonstrated superior survival benefits compared to standard of care.

Negatives

• General and administrative expenses have significantly increased, primarily due to legal and professional fees.
• The company experienced a net loss of $12.5 million for the three months ended June 30, 2024.
• The company's cash reserves decreased from $37.1 million at the end of 2023 to $24.5 million by the end of the second quarter of 2024.

Risks

• The company's ability to obtain sufficient additional capital to continue advancing FB102 is a risk.
• There are uncertainties associated with the clinical development and regulatory approval of FB102, including potential delays in clinical trials.
• Results from preclinical and early-stage clinical trials may not be predictive of future results.
• There is a risk of failure to realize any value from FB102 due to the inherent risks and difficulties in bringing product candidates to market.
• The company faces risks related to competition and the impact of government laws and regulations.

Future Outlook

Forte plans to advance the clinical development of FB102, including initiating a celiac disease patient study with data expected by the second quarter of 2025. The company also intends to explore the potential of FB102 across a variety of autoimmune and autoimmune-related diseases.

Management Comments

• Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences, stated that Forte continues to make excellent progress with FB102 and that the Phase 1 healthy volunteer study has successfully completed, demonstrating a good safety profile.
• Management believes the data to date supports the significant potential for FB102 across a variety of autoimmune and autoimmune-related diseases with large addressable markets.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for autoimmune diseases. The progress of FB102 and its potential in celiac disease and other autoimmune conditions positions Forte as a player in this space. The company is targeting areas with significant unmet medical needs, which is a common strategy in the biotech sector.

Comparison to Industry Standards

• Forte's FB102 is an anti-CD122 antibody, a mechanism that is being explored by other companies in the autoimmune space, but Forte's approach is unique in its selectivity for inhibiting pathogenic immune cells while sparing regulatory T cells.
• The company's preclinical data in a humanized mouse model of acute GVHD shows a 90% survival rate with FB102, which is comparable to or better than some existing treatments like Ruxolitinib, which showed 60% survival in the same model.
• Incyte's Ruxolitinib, a JAK 1/2 inhibitor, has shown a 62% overall response rate in second-line GVHD treatment, while Equillium/Ono's Itolizumab, an anti-CD6 antibody, has shown a >50% response rate in first-line GVHD treatment. Forte's FB102 is still in early clinical development, but the preclinical data suggests a promising efficacy profile.
• The celiac disease market has no approved therapies, making Forte's entry into this space with FB102 a potentially significant opportunity. Other companies are also exploring treatments for celiac disease, but Forte's approach with an anti-CD122 antibody is novel.

Related Party Transactions

• The document mentions a related party payable of $50 thousand as of June 30, 2024.

Stakeholder Impact

• Shareholders may view the progress of the FB102 program and the initiation of the celiac disease study positively.
• Employees may be encouraged by the company's progress and the potential of FB102.
• Patients with autoimmune diseases, particularly celiac disease, may benefit from the development of FB102.
• Creditors may be concerned about the decrease in cash reserves and the potential need for additional funding.

Next Steps

• Forte will initiate a patient study in celiac disease with first patient dosing expected in the third quarter of 2024.
• The company expects top-line results from the celiac disease study by the second quarter of 2025.
• Forte will continue to advance the FB102 program and explore its potential across various autoimmune and autoimmune-related diseases.

Key Dates

Keywords

FB102, autoimmune diseases, celiac disease, clinical trials, monoclonal antibody, biopharmaceutical, research and development, NK cells, Tregs, GvHD